Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions

Kieran Oldfield; Rohan Jayasinghe; Selvanayagam Niranjan; Sameer Chadha

doi:10.1136/bcr-2020-237217

Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions

Kieran Oldfield^*, Rohan Jayasinghe, Selvanayagam Niranjan, Sameer Chadha

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

37 Downloads (Pure)

Abstract

Immune checkpoint inhibitors (ICIs) are increasingly used to treat certain malignancies due to their higher efficacy compared with conventional chemotherapy. As familiarity with these agents increases, it is becoming apparent that a significant number of patients treated with ICIs experience adverse events. With time, more immune-related adverse events (IRAEs) are being recognised. It is important to be vigilant for IRAEs and recognise that a patient may have multiple IRAEs affecting multiple organ systems. Common cardiovascular adverse events associated with ICIs include myocarditis, arrhythmias and pericarditis. This case report identifies a patient presenting with takotsubo syndrome followed by ketoacidosis (associated with sodium-glucose transport protein 2 (SGLT2) inhibitor) in the setting of combination ipilimumab and nivolumab therapy for metastatic melanoma.

Original language	English
Article number	e237217
Pages (from-to)	1-4
Number of pages	4
Journal	BMJ Case Reports
Volume	14
Issue number	2
DOIs	https://doi.org/10.1136/bcr-2020-237217
Publication status	Published - 1 Feb 2021

Bibliographical note

Copyright BMJ Publishing Group 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

cancer - see oncology
cardiovascular medicine
diabetes
drugs and medicines
unwanted effects / adverse reactions

Access to Document

10.1136/bcr-2020-237217Licence: CC BY-NC

Publisher version (open access)Final published version, 1.13 MBLicence: CC BY-NC

Cite this

@article{cc226b2a177d4deab672c45ffc6e24ee,

title = "Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions",

abstract = "Immune checkpoint inhibitors (ICIs) are increasingly used to treat certain malignancies due to their higher efficacy compared with conventional chemotherapy. As familiarity with these agents increases, it is becoming apparent that a significant number of patients treated with ICIs experience adverse events. With time, more immune-related adverse events (IRAEs) are being recognised. It is important to be vigilant for IRAEs and recognise that a patient may have multiple IRAEs affecting multiple organ systems. Common cardiovascular adverse events associated with ICIs include myocarditis, arrhythmias and pericarditis. This case report identifies a patient presenting with takotsubo syndrome followed by ketoacidosis (associated with sodium-glucose transport protein 2 (SGLT2) inhibitor) in the setting of combination ipilimumab and nivolumab therapy for metastatic melanoma. ",

keywords = "cancer - see oncology, cardiovascular medicine, diabetes, drugs and medicines, unwanted effects / adverse reactions",

author = "Kieran Oldfield and Rohan Jayasinghe and Selvanayagam Niranjan and Sameer Chadha",

note = "Copyright BMJ Publishing Group 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2021",

month = feb,

day = "1",

doi = "10.1136/bcr-2020-237217",

language = "English",

volume = "14",

pages = "1--4",

journal = "BMJ Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

number = "2",

}

TY - JOUR

T1 - Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis

T2 - rare reactions

AU - Oldfield, Kieran

AU - Jayasinghe, Rohan

AU - Niranjan, Selvanayagam

AU - Chadha, Sameer

N1 - Copyright BMJ Publishing Group 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2021/2/1

Y1 - 2021/2/1

N2 - Immune checkpoint inhibitors (ICIs) are increasingly used to treat certain malignancies due to their higher efficacy compared with conventional chemotherapy. As familiarity with these agents increases, it is becoming apparent that a significant number of patients treated with ICIs experience adverse events. With time, more immune-related adverse events (IRAEs) are being recognised. It is important to be vigilant for IRAEs and recognise that a patient may have multiple IRAEs affecting multiple organ systems. Common cardiovascular adverse events associated with ICIs include myocarditis, arrhythmias and pericarditis. This case report identifies a patient presenting with takotsubo syndrome followed by ketoacidosis (associated with sodium-glucose transport protein 2 (SGLT2) inhibitor) in the setting of combination ipilimumab and nivolumab therapy for metastatic melanoma.

AB - Immune checkpoint inhibitors (ICIs) are increasingly used to treat certain malignancies due to their higher efficacy compared with conventional chemotherapy. As familiarity with these agents increases, it is becoming apparent that a significant number of patients treated with ICIs experience adverse events. With time, more immune-related adverse events (IRAEs) are being recognised. It is important to be vigilant for IRAEs and recognise that a patient may have multiple IRAEs affecting multiple organ systems. Common cardiovascular adverse events associated with ICIs include myocarditis, arrhythmias and pericarditis. This case report identifies a patient presenting with takotsubo syndrome followed by ketoacidosis (associated with sodium-glucose transport protein 2 (SGLT2) inhibitor) in the setting of combination ipilimumab and nivolumab therapy for metastatic melanoma.

KW - cancer - see oncology

KW - cardiovascular medicine

KW - diabetes

KW - drugs and medicines

KW - unwanted effects / adverse reactions

UR - http://www.scopus.com/inward/record.url?scp=85100510569&partnerID=8YFLogxK

U2 - 10.1136/bcr-2020-237217

DO - 10.1136/bcr-2020-237217

M3 - Article

C2 - 33526518

AN - SCOPUS:85100510569

SN - 1757-790X

VL - 14

SP - 1

EP - 4

JO - BMJ Case Reports

JF - BMJ Case Reports

IS - 2

M1 - e237217

ER -

Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this